I'm LongbridgeAI, I can summarize articles.NeuroThera Labs Inc. has announced the publication of an international patent in collaboration with Clearmind Medicine for a novel therapy targeting weight loss and metabolic dysfunction-associated steatotic liver disease (MASLD). The combination of 5-methoxy-2-aminoindane (MEAI) and Palmitoylethanolamide (PEA) aims to provide a safe, non-hallucinogenic treatment for obesity and MASLD, addressing a growing market projected to reach $226 billion by 2035. This collaboration seeks to meet the demand for effective treatments in the obesity and liver health sectors.
(TheNewswire)
Vancouver, British Columbia – March 11, 2026 –TheNewswire – NeuroThera
Labs Inc. (the "Company" or"NeuroThera"), a clinical-stage biotech company and a majority-owned subsidiary of SciSparc Ltd. (Nasdaq: SPRC), has advanced its collaboration with Clearmind Medicine Inc.with the publication of an international patent application under thePatent Cooperation Treaty (PCT) for a novel combination therapy aimedat treating weight loss and metabolic dysfunction-associated steatoticliver disease (MASLD, formerly known as fatty liver disease).
The patent publication highlights the potential of a 5-methoxy-2-aminoindane (MEAI)- Palmitoylethanolamide (PEA) combination to offer a safe,non-hallucinogenic neuroplastogen treatment for two major globalhealth challenges: obesity, affecting over 890
million adults worldwide, and MASLD,impacting approximately 30% of the global adult
population. Moreover, due to thepresumed mechanism of action of the combination, this therapeuticoption may offer a safer, easier and more cost effective option thanGLP-1s agonists for obesity and MASLD.
By combining Clearmind’s MEAI platform withNeuroThera’s PEA, the companies wish to address the escalatingdemand for effective, tolerable and safe treatments in the obesity andliver health space. This comes at a time when the global weight lossdrugs market is experiencing rapid growth, which was valued atapproximately $37 billion in 2025 and
is forecasted to reach $226 billion by 2035, driven by increasing awareness of obesity as a chronicdisease and the need for innovative alternatives to GLP-1agonists.
About NeuroThera Labs Inc.
NeuroThera Labs Inc. (TSXV: NTLX) is aclinical-stage pharmaceutical company focused on developing noveltherapeutics for central nervous system disorders and otherunderserved health conditions through collaborations and innovative combinations.
About Clearmind Medicine Inc.
Clearmind is a clinical-stage neuroplastogens pharmaceutical biotechcompany focused on the discovery and development of novelpsychedelic-derived therapeutics to solve widespread and underservedhealth problems, including alcohol use disorder. Its primary objectiveis to research and develop psychedelic-based compounds and attempt tocommercialize them as regulated medicines, foods, or supplements.Clearmind’s intellectual portfolio currently consists of nineteenpatent families, including 31 granted patents. Clearmind intends toseek additional patents for its compounds whenever warranted and willremain opportunistic regarding the acquisition of additionalintellectual property to build its portfolio. Shares of Clearmind arelisted for trading on Nasdaq under the symbol "CMND". Forfurther information, visit: https://www.clearmindmedicine.com
For further information, please contact:
Michal Efraty
IR Manager
NeuroThera Labs Inc.
Telephone: +972-3-7617108
Email: michal@efraty.com
Neither the TSXV nor its RegulationServices Provider (as that term is defined in the policies of theTSXV) accepts responsibility for the adequacy or accuracy of thisrelease.
Cautionary Noticeon Forward-Looking Statements
This press release containsstatements that constitute "forward-looking information"("forward-looking information") within the meaning of theapplicable Canadian securities legislation. All statements, other thanstatements of historical fact, are forward-looking information and arebased on expectations, estimates and projections as at the date ofthis news release. Any statement that discusses predictions,expectations, beliefs, plans, projections, objectives, assumptions,future events or performance (often but not always using phrases suchas "expects", or "does not expect", "isexpected", "anticipates" or "does notanticipate", "plans", "budget","scheduled", "forecasts", "estimates","believes" or "intends" or variations of suchwords and phrases or stating that certain actions, events or results"may" or "could", "would","might" or "will" be taken to occur or beachieved) are not statements of historical fact and may beforward-looking information.
Forward-looking information in thisnews release includes, without limitation, statements regarding: thepotential therapeutic benefits of the MEAI-PEA combination for thetreatment of obesity and metabolic dysfunction-associated steatoticliver disease (MASLD); the potential for the MEAI-PEA combination tooffer a safer, easier, and more cost-effective alternative to GLP-1agonists; the presumed mechanism of action of the combination therapy;the anticipated demand for novel treatments in the obesity and liverhealth space; projections regarding the growth and future value of theglobal weight loss drugs market; and the Company's ability toadvance the collaboration with Clearmind Medicine Inc. and develop thecombination therapy toward commercialization.
These statements are not guaranteesof future performance and undue reliance should not be placed on them.Such forward-looking information necessarily involves known andunknown risks and uncertainties, which may cause the Company'sactual performance and results to differ materially from anyprojections of future performance or results expressed or implied bysuch forward-looking information.
These risks and uncertaintiesinclude, but are not limited to: the early stage of development of theMEAI-PEA combination and the inherent uncertainty of preclinical andclinical outcomes; the risk that the combination therapy may not demonstratethe anticipated safety, efficacy, or cost-effectiveness advantagesover existing treatments, including GLP-1 agonists; the ability of theCompany and Clearmind Medicine Inc. to advance the collaboration onacceptable terms; the ability of the Company to obtain the requiredregulatory approvals; the ability of the Company to obtain andmaintain adequate patent protection for the combination therapy;compliance with applicable laws and regulations; the ability of theCompany to raise additional capital to fund future operations; generalbusiness, financial market, economic, competitive, political andsocial uncertainties; and other risks and uncertainties described inthe Company's public filings available on SEDAR+ at www.sedarplus.ca.
There can be no assurance thatforward-looking statements will prove to be accurate, and actualresults and future events could differ materially from thoseanticipated. Readers are cautioned not to place undue reliance onforward-looking information as there can be no assurance that theplans, intentions or expectations upon which they are placed willoccur. Such information, although considered reasonable by managementat the time of preparation, may prove to be incorrect and actualresults may differ materially from those anticipated. Except asrequired by law, the Company disclaims any intention and assumes noobligation to update or revise any forward-looking information toreflect actual results, whether as a result of new information, futureevents, changes in assumptions, changes in factors affecting suchforward-looking information or otherwise.
Copyright (c) 2026 TheNewswire - All rights reserved.